PAP
MLYS icon

Persistent Asset Partners’s Mineralys Therapeutics MLYS Stock Holding History

Persistent Asset Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389K Sell
14,410
-991
-6% -$27.2K 0.12% 142
2026
Q1 		$417K Buy
15,401
+7,985
+108% +$234K 0.16% 125
2025
Q4 		$269K Buy
+7,416
New +$297K 0.12% 194

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Persistent Asset Partners's MLYS Position: Q2 2026 in Review

Persistent Asset Partners reduced its Mineralys Therapeutics (MLYS) stake by 6.4% in Q2 2026, selling an estimated $27.2K and leaving 14,410 shares worth $389K. The position accounts for 0.12% of the portfolio, ranked #142.

Persistent Asset Partners first reported a position in MLYS in Q4 2025 and has held it in 3 quarters since. The position peaked at $417K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Persistent Asset Partners held 14,410 shares of Mineralys Therapeutics worth $389K as of Q2 2026.
  • Persistent Asset Partners sold 991 Mineralys Therapeutics shares in Q2 2026, an estimated $27.2K.
  • Mineralys Therapeutics made up 0.12% of Persistent Asset Partners's portfolio in Q2 2026, its #142 holding.
  • Persistent Asset Partners first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Mineralys Therapeutics position peaked at $417K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.